Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) have earned an average rating of “Moderate Buy” from the six ratings firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $13.6667.

Several research firms have commented on IVA. Guggenheim boosted their target price on shares of Inventiva from $9.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday. Piper Sandler began coverage on shares of Inventiva in a report on Wednesday, August 27th. They issued an “overweight” rating and a $26.00 price objective for the company.

Inventiva Trading Down 15.0%

Shares of Inventiva stock opened at $5.26 on Wednesday. The stock has a 50-day simple moving average of $3.75 and a 200-day simple moving average of $3.41. Inventiva has a 52-week low of $1.53 and a 52-week high of $6.50.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Inventiva stock. Wealth Enhancement Advisory Services LLC bought a new position in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 10,715 shares of the company’s stock, valued at approximately $32,000. 19.06% of the stock is currently owned by institutional investors and hedge funds.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.